At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Multicenter, Multinational, Placebo Controlled, Parallel Group, Single Dose, Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke
In Brief
A Phase 3 clinical trial evaluating Intravenous glenzocimab (ACT017) 1000 mg and Intravenous Placebo for Acute Ischemic Stroke. Completed, enrolled 438 participants across 10 sites in 2 countries.
Detailed Summary
A randomized, double blind, multicenter, multinational, placebo controlled, parallel group, single dose, adaptive phase II/III study. The study evaluates the efficacy and safety of a fixed dose of glenzocimab (1000 mg IV over 6 hrs including initial bolus of 15 minutes) on top of the best standard of care.
Study Details
Timeline
Interventions
Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms